tiprankstipranks
Trending News
More News >
Ceribell, Inc. (CBLL)
NASDAQ:CBLL
US Market
Advertisement

Ceribell, Inc. (CBLL) AI Stock Analysis

Compare
51 Followers

Top Page

CBLL

Ceribell, Inc.

(NASDAQ:CBLL)

Rating:48Neutral
Price Target:
$15.00
▼(-0.86%Downside)
Ceribell's impressive revenue growth is overshadowed by profitability challenges and reliance on external funding. Technical indicators and valuation concerns suggest caution. The earnings call provided some optimism, but legal proceedings introduce additional risks.
Positive Factors
Intellectual Property
Ceribell's management is confident in its intellectual property as a significant barrier to entry for competitors.
New Market Expansion
Ceribell's pipeline consists of initiatives designed to expand its Total Addressable Market, including recent label expansion into pediatrics and plans for extension into neonates and new indications like delirium and ischemic stroke.
Revenue Growth
Ceribell reported full-year gross margins of ~87% and $65.4M in total revenue, which represents 45% year-over-year growth.
Negative Factors
Geopolitical Risks
Ceribell is exposed to geopolitical risk due to its China-based manufacturing operations, which could impact gross margins with potential tariff changes.
Patent Dispute
Ceribell announced a lawsuit against Natus Medical, alleging patent infringement on its BrainWatch EEG system.
Stock Pressure
The stock has fallen 35% largely due to China manufacturing exposure and lock-up expiration.

Ceribell, Inc. (CBLL) vs. SPDR S&P 500 ETF (SPY)

Ceribell, Inc. Business Overview & Revenue Model

Company DescriptionCeriBell, Inc. develops AI based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. The company develops Ceribell System, a novel, point-of-care EEG platform to address the unmet needs of patients in the acute care setting. It also offers EEG disposable headbands; and pocket-sized battery-operated recorders. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. The company was incorporated in 2014 and is based in Sunnyvale, California.
How the Company Makes MoneyCeribell, Inc. generates revenue primarily through the sale of its EEG systems to hospitals and medical institutions. The company's revenue model includes the direct sale of its EEG hardware, as well as recurring revenue from the consumables and accessories required for the operation of these systems. Additionally, Ceribell may offer service contracts and training for healthcare providers to ensure proper usage and maintenance of their equipment. Significant partnerships with hospitals, healthcare systems, and potentially government health bodies could contribute to the company's earnings by facilitating broader adoption of their technology.

Ceribell, Inc. Earnings Call Summary

Earnings Call Date:May 08, 2025
(Q1-2025)
|
% Change Since: -11.52%|
Next Earnings Date:Aug 05, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant revenue growth, high gross margins, expansion of active accounts, and important regulatory achievements, such as FDA clearance and FedRAMP authorization. However, the increase in operating expenses and net loss, along with potential impacts from increased tariffs, present challenges. Despite these lowlights, the positive aspects, including strategic achievements and financial growth, suggest a confident outlook.
Q1-2025 Updates
Positive Updates
Strong Revenue Growth
CeriBell, Inc. reported total revenue of $20.5 million for Q1 2025, marking a 42% increase over the same period last year and an 11% increase over Q4 2024.
High Gross Margin
The company achieved a gross margin of 88% in Q1 2025, compared to 86% in the prior year period, indicating strong profitability.
Expansion of Active Accounts
The company increased its active accounts to 558 as of March 31, 2025, adding 29 new accounts in Q1, including the integration of its clarity algorithm in VA hospitals.
FDA Clearance and Product Expansion
CeriBell, Inc. received FDA 510(k) clearance for its Clarity algorithm for seizure detection in pediatric patients, expanding the addressable patient population significantly.
FedRAMP High Authorization Achieved
CeriBell, Inc. received FedRAMP high authorization from the US government, validating its cybersecurity standards and enabling use by other government agencies.
Negative Updates
Increased Operating Expenses
Total operating expenses for Q1 2025 were $32.2 million, a 55% increase from the same period in 2024, primarily due to expanded commercial operations and increased headcount.
Net Loss Increased
The company reported a net loss of $12.8 million for Q1 2025, compared to a loss of $8.5 million in Q1 2024, influenced by higher operating expenses.
Potential Tariff Impact
The company anticipates potential impacts on gross margins due to increased tariffs on goods imported from China, though mitigation strategies are in place.
Company Guidance
In the CeriBell, Inc. Q1 2025 earnings call, the company reported a robust start to the year with total revenue of $20.5 million, marking a 42% increase compared to the same period last year. The company experienced 88% gross margin, reflecting its strategic success in account acquisition and utilization. CeriBell added 29 new accounts, reaching a total of 558 active accounts, including its first cohort of VA hospitals. The company also received FedRAMP high authorization, enhancing its cybersecurity credentials. For 2025, CeriBell raised its revenue guidance to $83-$87 million, reflecting an annual growth of 27% to 33%. Despite potential tariff impacts, the company expects to maintain gross margins in the mid-80% range, leveraging its U.S. inventory and cost reduction strategies. The company is also confident in reaching cash flow breakeven with its current cash on hand, totaling $182.7 million as of March 31, 2025.

Ceribell, Inc. Financial Statement Overview

Summary
Ceribell, Inc. demonstrates strong revenue growth and improved equity, suggesting financial stability. However, negative net profit margins, high operating expenses, and reliance on external financing reveal significant profitability and cash management challenges.
Income Statement
45
Neutral
Ceribell, Inc. shows solid revenue growth of 44.7% from 2023 to 2024, highlighting strong demand for their products. However, the company is operating at a loss with a negative net profit margin, and EBIT and EBITDA margins indicate inefficiencies. Gross profit margins are strong at approximately 86.7% for 2024, signifying good production cost management but are overshadowed by the high operating expenses.
Balance Sheet
60
Neutral
The company's equity has significantly improved from negative to a strong positive position in 2024, indicating strong financial backing or recent capital infusion. The debt-to-equity ratio is low due to high equity, showcasing low leverage risk. However, the equity ratio is high at 84.8%, reflecting a stable asset base primarily funded by equity.
Cash Flow
50
Neutral
Ceribell's free cash flow is negative but has shown improvement from 2023. The high operating cash outflows are concerning, relative to the negative net income, indicating cash management issues. A significant financing cash flow in 2024 suggests reliance on external funding to cover operational deficits.
BreakdownTTMDec 2024Dec 2023Dec 2022
Income Statement
Total Revenue71.08M65.44M45.23M25.92M
Gross Profit62.01M56.75M38.16M21.49M
EBITDA-43.74M-37.71M-26.51M-35.06M
Net Income-44.50M-40.45M-29.46M-37.16M
Balance Sheet
Total Assets213.47M225.41M58.92M86.46M
Cash, Cash Equivalents and Short-Term Investments182.70M194.37M34.49M68.23M
Total Debt21.76M21.96M14.20M18.22M
Total Liabilities20.76M34.25M171.17M172.86M
Stockholders Equity180.88M191.16M-112.25M-86.40M
Cash Flow
Free Cash Flow-39.90M-36.38M-30.14M-32.52M
Operating Cash Flow-38.18M-35.04M-29.16M-32.00M
Investing Cash Flow-30.56M-1.60M-1.76M-1.40M
Financing Cash Flow192.68M196.52M-2.82M49.80M

Ceribell, Inc. Risk Analysis

Ceribell, Inc. disclosed 79 risk factors in its most recent earnings report. Ceribell, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Ceribell, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
81
Outperform
$719.68M36.6023.81%1.14%11.04%9.84%
63
Neutral
$601.64M-7.22%18.81%67.41%
52
Neutral
$549.38M45.80-36.78%1.34%-530.36%
50
Neutral
$514.36M-29.16%25.77%49.44%
48
Neutral
$555.88M26.25%
46
Neutral
C$201.68M-3.23-23.14%1.87%20.75%-0.36%
45
Neutral
$322.66M-11.98%46.69%46.68%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CBLL
Ceribell, Inc.
15.13
-10.37
-40.67%
AXGN
AxoGen
13.37
4.46
50.06%
IRMD
Iradimed
56.32
10.17
22.04%
AVNS
Avanos Medical
12.01
-10.87
-47.51%
BFLY
Butterfly Network
1.97
0.93
89.42%
RXST
RxSight
7.97
-36.75
-82.18%

Ceribell, Inc. Corporate Events

Legal Proceedings
Ceribell Files Patent Infringement Complaints Against Natus
Negative
Jul 7, 2025

On July 7, 2025, Ceribell, Inc. announced it filed complaints against Natus Medical Incorporated with the U.S. International Trade Commission and the U.S. District Court for the District of Delaware, alleging patent infringement and unfair competition related to its EEG headband and electrode design. Ceribell seeks to protect its intellectual property and maintain fair competition, requesting an investigation and exclusion order to prevent the importation of infringing Natus products into the U.S., highlighting its commitment to innovation in point-of-care EEG technology.

The most recent analyst rating on (CBLL) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Ceribell, Inc. stock, see the CBLL Stock Forecast page.

Business Operations and Strategy
Ceribell Extends Exclusive License with Stanford University
Neutral
Jun 20, 2025

Ceribell, Inc. and Stanford University have amended their exclusive agreement, initially effective from June 15, 2015, to extend the exclusivity of Ceribell’s license for certain portable brain wave activity devices. On June 12, 2025, Ceribell exercised an option to extend this exclusivity by paying a $250,000 fee, which impacts the company’s operations by securing continued access to patented technology.

The most recent analyst rating on (CBLL) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Ceribell, Inc. stock, see the CBLL Stock Forecast page.

Executive/Board ChangesShareholder Meetings
Ceribell, Inc. Announces Results of Annual Meeting
Neutral
Jun 12, 2025

On June 10, 2025, Ceribell, Inc. held its Annual Meeting of Stockholders, where two key proposals were voted on. The stockholders elected Juliet Tammenoms Bakker and Lucian Iancovici, M.D. as Class I directors to serve until the 2028 meeting, and approved the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (CBLL) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Ceribell, Inc. stock, see the CBLL Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 22, 2025